Table 4.
Simultaneous estimated population pharmacodynamic parameters following treatment with the gonadotropin-releasing hormone (GnRH) agonist triptorelin and the GnRH receptor blocker degarelix
| Population mean | IIV | ||||
|---|---|---|---|---|---|
| Parameter | Unit | Estimate | (RSE, %) | CV (%) | (RSE, %) |
| ke,LH* | (l h−1) | 0.0082 | (1.56) | – | – |
| ke,LH† | (l h−1) | 0.535 | (4.14) | – | – |
| krel,LH | (l h−1) | 0.00241 | (6.36) | 83.4 | (3.25) |
| Emax | (–) | 1330 | (8.58) | – | – |
| EC50 | (ng ml−1) | 0.047 | (5.53) | 32.7 | (13.4) |
| γ | (–) | 4.87 | (3.69) | – | – |
| Imax | (–) | 0.942 | (0.155) | – | – |
| IC50 | (ng ml−1) | 1.49 | (5.04) | 59.5 | (6.44) |
| δ | (–) | 1.97 | (3.45) | 38.9 | (6.73) |
| ke,F* | (l h−1) | 0.00107 | (8.26) | 59.1 | (4.69) |
| ke,F† | (l h−1) | 0.00497 | (4.87) | 59.1 | (4.69) |
| λ* | (–) | 8.26 | (3.65) | – | – |
| λ† | (–) | 0.56 | (1.00) | – | – |
| ke,Te | (l h−1) | 0.0901 | (2.72) | – | – |
| Lmax | (–) | 77.5 | (3.51) | 51.7 | (6.24) |
| L50 | (IU l−1) | 5.18 | (2.98) | 46.0 | (5.42) |
| κ | (–) | 1.9 | (0.836) | – | – |
| LHbase* | (IU l−1) | 4.76 | (1.80) | – | – |
| LHbase† | (IU l−1) | 6.98 | (1.34) | – | – |
| Tebase* | (ng ml−1) | 4.85 | (1.64) | – | – |
| Tebase† | (ng ml−1) | 3.21 | (1.47) | – | – |
| σLH | (%) | 41.9 | (1.00) | – | – |
| σTe | (%) | 49.4 | (0.983) | – | – |
*
Triptorelin study-specific parameter.
†
Degarelix study-specific parameter.